|
|
Article: Geron Receives U.S. Patent for Human Telomerase Promoter Triggering Milestone Payment.
- Article from:
- Business Wire
- Article date:
- August 26, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 26, 2003
Geron Corporation (Nasdaq:GERN) announced today that it has been granted U.S. Patent No. 6,610,839, by the U.S. Patent and Trademark Office, with claims covering the promoter that regulates expression of the human telomerase reverse transcriptase gene (the "hTERT promoter"). Geron had non-exclusively licensed the hTERT promoter to Genetic Therapy, Inc. ("GTI"), a subsidiary of Novartis AG, for use in the development of viruses that are designed to target cancer cells. Cell Genesys, Inc. (Nasdaq:CEGE) recently acquired rights to the GTI product portfolio and ...